Azenta Faces Delay in B Medical Systems Divestiture

The latest announcement is out from Azenta ( (AZTA) ).

Azenta, Inc. disclosed that a planned sale of the entire issued share capital of its subsidiary B Medical Systems S.À R.L. to Thelema S.À R.L., initially expected to close on or before March 31, 2026, did not close as scheduled because Thelema had not secured the required residual financing as of March 27, 2026. The transaction remains pending and subject to all closing conditions, and while the parties have neither amended nor terminated their agreement, Azenta is evaluating potential paths forward as Thelema seeks to complete its financing, leaving uncertainty around timing and execution for stakeholders.

The most recent analyst rating on (AZTA) stock is a Hold with a $21.00 price target. To see the full list of analyst forecasts on Azenta stock, see the AZTA Stock Forecast page.

Spark’s Take on AZTA Stock

According to Spark, TipRanks’ AI Analyst, AZTA is a Neutral.

AZTA scores as a mid-range setup driven by strong financial flexibility (low leverage, substantial cash, and positive recent cash flow) and reaffirmed improvement targets, but weighed down by very weak technical momentum and ongoing profitability/margin pressures. Valuation is also less supportive due to losses (negative P/E) and no dividend yield provided.

To see Spark’s full report on AZTA stock, click here.

More about Azenta

Azenta, Inc., through its wholly owned subsidiary Azenta Germany GmbH, operates in the life sciences and related technology sector, focusing on specialized solutions that include controlled storage and systems for biological and medical applications. The company’s portfolio has included assets such as B Medical Systems S.À R.L., reflecting a strategic focus on temperature-controlled and medical storage technologies.

Average Trading Volume: 864,935

Technical Sentiment Signal: Sell

Current Market Cap: $975.6M

Learn more about AZTA stock on TipRanks’ Stock Analysis page.